Collegium Pharmaceutical said ADHD drugs now make up 36% of total revenue, up from 19% a year earlier. Growth came from Jornay PM, whose adult segment rose 27% year over year, and from Azstarys, which reversed a prior decline in prescriptions. The company's pain portfolio is shrinking. Nucynta revenue fell 44% on generic competition, and Xtampza revenue also declined under payer pressure. Collegium expects an Xtampza payer win covering 15 million lives to give it exclusive formulary status from January 1, 2027. Full-year guidance sees Jornay PM revenue growing about 31% at the midpoint. In the third quarter, Collegium started a $50 million accelerated share repurchase, due to finish before year-end. Management is watching for a possible generic Belbuca launch by Teva in January 2027.

Collegium Pharmaceutical reported record third-quarter net revenue of $216.3 million, up 3% year-over-year. Adjusted EBITDA fell 9% to $121.6 million, while GAAP net income dropped to $21.8 million from $31.5 million. ADHD drugs drove growth. JORNAY PM revenue rose 24% to $51.9 million, and AZSTARYS brought in $26.5 million in its first full quarter under Collegium's ownership. Pain portfolio revenue fell 18% to $138.0 million. The company reaffirmed its 2026 guidance of $825 million to $855 million in net product revenue and $445 million to $470 million in adjusted EBITDA. It expects to finish a $50 million accelerated share repurchase by year-end.

Collegium Pharmaceutical (NASDAQ:COLL) now covered by Oppenheimer. September 23, 2026 Key points. * Oppenheimer initiated coverage of Collegium Pharmaceutical with an "outperform" rating and a $50 price target, implying approximately 119.5% upside from the stock's $22.78 price. * Analyst sentiment is mixed but leans positive: six analysts rate the stock a Buy, two a Hold, and one a Sell, producing a "Moderate Buy" consensus and an average price target of $48.71. * Collegium exceeded quarterly expectations, reporting $1.92 in EPS versus the $1.72 estimate and $199.88 million in revenue; revenue increased 6.3% year over year. * MarketBeat previews the top five stocks to own by October 1st. Analysts at Oppenheimer assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $50.00 price target on the specialty pharmaceutical company's stock. Oppenheimer's target price points to a potential upside of 119.49% from the stock's current price. Several other research firms have also commented on COLL. Needham & Company LLC cut their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, September 4th. Finally, Truist Financial started coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a "buy" rating and a $49.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $48.71. Collegium Pharmaceutical price performance. COLL stock opened at $22.78 on Wednesday. The stock has a 50-day moving average price of $28.68 and a two-hundred day moving average price of $32.45. Collegium Pharmaceutical has a 12-month low of $21.65 and a 12-month high of $50.79. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The company has a market cap of $741.72 million, a PE ratio of 18.37 and a beta of 0.72. Discover more AI Stocks Analysis Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business posted $1.68 EPS. As a group, research analysts predict that Collegium Pharmaceutical will post 6.19 EPS for the current year. Hedge funds weigh in on Collegium Pharmaceutical. Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its stake in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company's stock worth $29,000 after buying an additional 427 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 418 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Collegium Pharmaceutical by 51.8% during the 4th quarter. Hantz Financial Services Inc. now owns 2,602 shares of the specialty pharmaceutical company's stock valued at $120,000 after acquiring an additional 888 shares during the last quarter. Assetmark Inc. boosted its stake in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company's stock valued at $130,000 after acquiring an additional 335 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 17.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,174 shares of the specialty pharmaceutical company's stock worth $193,000 after acquiring an additional 611 shares in the last quarter. Collegium Pharmaceutical company profile. Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company's portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs. Collegium's pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Collegium Pharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list. While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates. Continue following MarketBeat